Jan 26, 2014 by Peter StephensNovartis: Running Fast to Stand Still?Novartis' recent setback may not be all bad news for the company’s long-term prospects.
Jan 26, 2014 by Peter Stephens3 Reasons to Focus on DiabetesWith demand for diabetes drugs set to increase rapidly, AstraZeneca, Bristol-Myers Squibb, and Pfizer appear to be well placed to benefit.
Jan 22, 2014 by Peter StephensWhy Medtronic Is The Early Bird That Could Catch The WormEarly FDA approval could make Medtronic a stock to watch.
Jan 21, 2014 by Peter StephensWho Cares About Guidance, Anyway? Investors in St. Jude, That's Who!Improved sales in Q4 mean that St Jude Medical has raised its guidance for the quarter. The stock could be one to watch in 2014.
Jan 19, 2014 by Peter StephensDivestment Is the Name of the Game for Johnson & JohnsonRecent news flow highlights the encouraging progress made by Johnson & Johnson (JNJ) as it seeks top-line growth.
Jan 19, 2014 by Peter StephensIs the Uncertainty at Novartis a Game-Changer for Investors?Recent management changes at Novartis AG (NVS) is something for shareholders to note.
Jan 19, 2014 by Peter Stephens3 Ways to Get Wealthier (and Healthier)A recent study shows Americans are getting healthier. How could they get wealthier, too?
Jan 19, 2014 by Peter StephensA Roller-Coaster Ride With Intercept Pharmaceuticals2014 has been full of (mainly) ups and (some) downs for Intercept Pharmaceuticals (ICPT).
Jan 9, 2014 by Peter StephensBoston Scientific Corporation: Your Next Turnaround Story?Boston Scientific Corporation seems to have the potential to be a major turnaround play.
Jan 8, 2014 by Peter StephensWhy the Risk/Reward Ratio Looks Great for Regeneron Pharmaceuticals Inc.There’s risk, but there could be vast rewards for Regeneron Pharmaceuticals Inc.
Jan 8, 2014 by Peter StephensCan AbbVie Crush the Market in 2014?AbbVie Inc. (ABBV) is a hot pharma stock.
Jan 7, 2014 by Peter StephensWhy Obamacare and Hospira Inc. Are The Perfect Fit... and why Hospira Inc. looks like a solid investment.
Jan 6, 2014 by Peter StephensWhy Tapering Is Great News for Allergan Inc.How growth stocks like Allergan could benefit from tapering.
Dec 18, 2013 by Peter StephensAmarin, Vivus, and Teva: The 3 Biggest Management Shake-Ups of 2013Forget Steve Ballmer and Ron Johnson. These are the management shake-ups that health-care investors were watching this year.
Dec 17, 2013 by Peter StephensCash Is King for PfizerThe cash keeps on coming at Pfizer, but is it being used wisely?
Dec 17, 2013 by Peter Stephens3 Reasons Why Bristol-Myers Squibb Could Make an Awesome ComebackHere’s why Bristol-Myers Squibb could become the King of Comebacks.
Dec 12, 2013 by Peter Stephens3 Reasons Why Johnson & Johnson Could Help You Retire EarlyRetirement may not be too far away for investors in Johnson & Johnson. Here’s why.
